PSY12 Economic Burden of Severe Atopic Dermatitis in Russia

Abstract

Severe atopic dermatitis (AD) characterizes by permanent exacerbations that leads to sufferings and influences on physical and emotional conditions and losses of patient’s productivity. Modern drugs including biologicals have a good clinical efficacy, but the same time economic burden of AD in the Russia are not evaluated yet. The main aim of this study was to perform cost-of-illness analysis of severe AD in adult patients. Analysis of the published clinical trials was conducted to evaluate costs associated with severe AD in Russia. A dermatologist survey was conducted to evaluate current practice of the management of adult patients with AD. MS Excel based model of medical care adult patients with severe AD has been developed. Time horizon was 1 year. To measure costs of AD were used “cost-of-illness” analysis. Direct medical and non-medical costs, indirect costs based on prevalence data, statistics of finances covering of out-patients and in-patients treatment options, experts’ opinions, reports about temporary disability, losses of GDP etc. have been calculated. Costs of severe AD in typical practice evaluated as 564242 RUR/patient/year ($7909 per patient/year) in working age and 263230 RUR/patient/year ($3689 per patient/year) in aged population. Economic burden of severe AD in the Russia can reach 13.1 bln RUR ($183.3 mln) annually (12.03 bln RUR ($168.6 mln) for working patients and 1.043 bln RUR ($14.6 mln) for aged population of patients) (rate for July 2020). Direct non-medical and indirect costs have at least 50 % of all expenditures that highlighting of social importance of severe AD. Severe AD generates considerable usage of health care resources and high costs for the Russian Healthcare System. These are in proportion with the severity of the disease.